altsonflex1-2-3
Vaccineexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 6, 2021 (NCT05073003)
Timeline
Indications
Studied for
Mechanism of action
- Shigella flexneriImmunity, active
Shigella flexneri immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06663436 | Phase 2 | Nov 4, 2024 | GlaxoSmithKline |
| NCT05073003 | Phase 1/Phase 2 (Phase 2) | Oct 6, 2021 | GlaxoSmithKline |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 2 | 2 | 1 | 2021 |
1 organizations
Page 1 / 1